In ADNI, AD A+T− had a higher baseline tau‐PET SUVR in the early‐stage tau ROI compared to both control groups and a higher baseline tau‐PET SUVR in the late‐stage tau ROI compared to CU A−T− (Figure 1 and Table 1) (all estimates and p values are listed in Table S1). This evidence concerns the gene MAPT and Alzheimer disease.